Use of Oral Corticosteroids to Treat HTLV-1-Associated Myelopathy (HAM) in Sao Paulo, Brazil

Imagem de Miniatura
Arquivos
art_DAHY_Use_of_Oral_Corticosteroids_to_Treat_HTLV1Associated_Myelopathy_2023.PDF (506.36 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
DAHY, Flavia Esper
MARCUSSO, Rosa M. N.
MOURA, Joao V. Luisi de
HAZIOT, Michel E. J.
VIDAL, Jose E.
SMID, Jerusa
OLIVEIRA, Augusto C. Penalva de
Citação
MICROBIOLOGY RESEARCH, v.14, n.2, p.646-655, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Simple Summary Our findings provide observational evidence supporting oral corticosteroids therapy as maintenance therapy for HTLV-1-associated myelopathy (HAM). The daily use of oral, low-dose prednisone seems to be useful in some subsets of HAM patients and needs to be evaluated in randomized controlled trials. Background: During the development of human T-cell lymphotropic virus (HTLV-1)-associated myelopathy (HAM), the inflammatory phenomenon is very prominent and is a major factor in the outcome of the disease. The use of corticosteroids can modify their natural history, and in this study, we evaluated the effectiveness of using daily low-dose prednisone. Methods: This was a cross-sectional study using data collected by physicians monitoring patients with HAM at the Institute of Infectious Diseases ""Emilio Ribas"", the main referral center for patients with infectious diseases in Sao Paulo, Brazil. The objective was to determine if daily low-dose oral prednisone would be able to stabilize the progression of HAM. The outcome measure was a change in the Osame Motor Disability Score (OMDS). Results: Fifty-four patients used treatment with oral prednisone, 5 milligrams daily. Nine cases were excluded from the study because they did not have at least two rating scales within a minimum interval of one year, and six were excluded for being co-infected with HIV and/or HCV. Thirty-nine patients met this criterion and were included for analysis. The majority were women (71.8%), the mean age was 56.51 years old (SD & PLUSMN; 9.74), and the median time of use of prednisone was 16 months. Thirty-two patients (82.05%) maintained the same OMDS, 5/39 (12.82%) had clinical worsening, and 2/39 (5.13%) improved. Conclusions: There was a trend toward clinical stability with the use of oral corticosteroids. However, randomized controlled trials are necessary to evaluate the use in clinical practices in all stages of HAM.
Palavras-chave
human T-lymphotropic virus 1, HTLV-1-associated myelopathy, prednisone, treatment, Brazil
URI
https://observatorio.fm.usp.br/handle/OPI/54653
Referências
  1. Ahuja J, 2007, BIOMED PHARMACOTHER, V61, P201, DOI 10.1016/j.biopha.2007.02.006
  2. Araujo A Q, 1993, Arq Neuropsiquiatr, V51, P325
  3. Araujo A, 2021, NEUROL-CLIN PRACT, V11, P49, DOI 10.1212/CPJ.0000000000000832
  4. Assone T, 2018, VIRUS RES, V244, P71, DOI 10.1016/j.virusres.2017.11.010
  5. Best I, 2006, CLIN EXP IMMUNOL, V146, P226, DOI 10.1111/j.1365-2249.2006.03208.x
  6. Coler-Reilly ALG, 2017, NEUROTHERAPEUTICS, V14, P1084, DOI 10.1007/s13311-017-0533-z
  7. Croda MG, 2008, J NEUROL SCI, V269, P133, DOI 10.1016/j.jns.2008.01.004
  8. De Castro-Costa CM, 2006, AIDS RES HUM RETROV, V22, P931, DOI 10.1089/aid.2006.22.931
  9. Einsiedel LJ, 2016, MED J AUSTRALIA, V205, P305, DOI 10.5694/mja16.00285
  10. Enose-Akahata Y, 2021, ANN CLIN TRANSL NEUR, V8, P1970, DOI 10.1002/acn3.51437
  11. Espindola OM, 2015, INTERVIROLOGY, V58, P106, DOI 10.1159/000371766
  12. Gessain A, 2012, REV NEUROL-FRANCE, V168, P257, DOI 10.1016/j.neurol.2011.12.006
  13. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  14. Haziot ME, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006967
  15. Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7
  16. Iwanaga M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01124
  17. Marcusso RMN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9010025
  18. Montanheiro P, 2007, J NEUROIMMUNOL, V188, P138, DOI 10.1016/j.jneuroim.2007.05.015
  19. Nakagawa M, 1996, J NEUROVIROL, V2, P345, DOI 10.3109/13550289609146899
  20. Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280260422668
  21. Prates G, 2021, NEUROL-CLIN PRACT, V11, P134, DOI 10.1212/CPJ.0000000000000866
  22. Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
  23. Puccioni-Sohler M, 2007, NEUROLOGY, V68, P206, DOI 10.1212/01.wnl.0000251300.24540.c4
  24. Puccioni-Sohler M, 2022, AIDS RES HUM RETROV, V38, P924, DOI [10.1089/AID.2022.0028, 10.1089/aid.2022.0028]
  25. Rosadas C., 2020, SVS MS, V51, P102274
  26. Sato T, 2018, NEW ENGL J MED, V378, P529, DOI 10.1056/NEJMoa1704827
  27. Tanajura D, 2015, CLIN INFECT DIS, V61, P49, DOI 10.1093/cid/civ229
  28. de Andrade CLT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243126
  29. Taylor GP, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-63
  30. YAMAMOTO JK, 1986, J INTERFERON RES, V6, P143, DOI 10.1089/jir.1986.6.143
  31. Yamano Yoshihisa, 2013, Nihon Rinsho, V71, P870
  32. Yamauchi J, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14010136
  33. Yamauchi J, 2020, J NEUROL NEUROSUR PS, V91, P321, DOI 10.1136/jnnp-2019-321955

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/IMREA
Artigos e Materiais de Revistas Científicas - LIM/40
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03